Investor AB comments on the withdrawal of Agnafit Bidco’s bid for Sobi
Upon the announcement of Agnafit Bidco’s SEK 235 per share bid for Sobi on September 2, 2021, Investor AB, in line with the recommendation by Sobi’s Board of Directors, declared its support for the bid. As announced earlier today, Agnafit Bidco has decided to withdraw its bid for Sobi, following insufficient acceptance of the bid. “We were instrumental in the creation of Sobi more than ten years ago. Under our ownership Sobi has built a leading hemophilia franchise greatly benefitting patients and broadened its product portfolio within Hematology and Immunology, organically and through